SMMT
Price
$23.46
Change
-$0.00 (-0.00%)
Updated
Oct 16 closing price
20 days until earnings call
SPHRY
Price
$0.76
Change
-$0.00 (-0.00%)
Updated
Sep 25 closing price
26 days until earnings call
Ad is loading...

SMMT vs SPHRY

Header iconSMMT vs SPHRY Comparison
Open Charts SMMT vs SPHRYBanner chart's image
Summit Therapeutics
Price$23.46
Change-$0.00 (-0.00%)
Volume$4.69M
CapitalizationN/A
Starpharma Holdings
Price$0.76
Change-$0.00 (-0.00%)
Volume$4K
CapitalizationN/A
View a ticker or compare two or three
SMMT vs SPHRY Comparison Chart
Loading...
SMMT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
SMMT vs. SPHRY commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SMMT is a StrongSell and SPHRY is a Hold.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (SMMT: $21.57 vs. SPHRY: $0.54)
Brand notoriety: SMMT and SPHRY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SMMT: 52% vs. SPHRY: 31%
Market capitalization -- SMMT: $15.35B vs. SPHRY: $28.84M
SMMT [@Biotechnology] is valued at $15.35B. SPHRY’s [@Biotechnology] market capitalization is $28.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SMMT’s FA Score shows that 2 FA rating(s) are green whileSPHRY’s FA Score has 1 green FA rating(s).

  • SMMT’s FA Score: 2 green, 3 red.
  • SPHRY’s FA Score: 1 green, 4 red.
According to our system of comparison, SMMT is a better buy in the long-term than SPHRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SMMT’s TA Score shows that 3 TA indicator(s) are bullish.

  • SMMT’s TA Score: 3 bullish, 5 bearish.

Price Growth

SMMT (@Biotechnology) experienced а +15.91% price change this week, while SPHRY (@Biotechnology) price change was -8.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

SMMT is expected to report earnings on Mar 13, 2025.

SPHRY is expected to report earnings on Nov 12, 2024.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($15.3B) has a higher market cap than SPHRY($28.8M). SMMT YTD gains are higher at: 798.851 vs. SPHRY (-43.730).
SMMTSPHRYSMMT / SPHRY
Capitalization15.3B28.8M53,125%
EBITDA-147.89MN/A-
Gain YTD798.851-43.730-1,827%
P/E Ratio26.36N/A-
Revenue0N/A-
Total Cash325MN/A-
Total Debt109MN/A-
FUNDAMENTALS RATINGS
SMMT vs SPHRY: Fundamental Ratings
SMMT
SPHRY
OUTLOOK RATING
1..100
6130
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
18100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
3457
P/E GROWTH RATING
1..100
12100
SEASONALITY SCORE
1..100
5047

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPHRY's Valuation (28) in the null industry is significantly better than the same rating for SMMT (96) in the Biotechnology industry. This means that SPHRY’s stock grew significantly faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (18) in the Biotechnology industry is significantly better than the same rating for SPHRY (100) in the null industry. This means that SMMT’s stock grew significantly faster than SPHRY’s over the last 12 months.

SPHRY's SMR Rating (96) in the null industry is in the same range as SMMT (98) in the Biotechnology industry. This means that SPHRY’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Price Growth Rating (34) in the Biotechnology industry is in the same range as SPHRY (57) in the null industry. This means that SMMT’s stock grew similarly to SPHRY’s over the last 12 months.

SMMT's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for SPHRY (100) in the null industry. This means that SMMT’s stock grew significantly faster than SPHRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SMMT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
Declines
ODDS (%)
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
SMMT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME21.660.39
+1.83%
GameStop Corp
BTC.X67612.720000571.609400
+0.85%
Bitcoin cryptocurrency
TSLA221.331.76
+0.80%
Tesla
SPY582.302.52
+0.43%
SPDR® S&P 500® ETF Trust
AAPL231.78-2.07
-0.89%
Apple

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
+7.42%
BCDA - SMMT
70%
Closely correlated
+7.99%
VBIZF - SMMT
42%
Loosely correlated
N/A
DAWN - SMMT
32%
Poorly correlated
+1.21%
ERNA - SMMT
31%
Poorly correlated
+0.84%
IDYA - SMMT
30%
Poorly correlated
+0.58%
More

SPHRY and

Correlation & Price change

A.I.dvisor tells us that SPHRY and TTNP have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPHRY and TTNP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHRY
1D Price
Change %
SPHRY100%
N/A
TTNP - SPHRY
29%
Poorly correlated
+2.98%
VACBF - SPHRY
28%
Poorly correlated
N/A
ZBIO - SPHRY
24%
Poorly correlated
-1.27%
ASPHF - SPHRY
23%
Poorly correlated
N/A
SMMT - SPHRY
21%
Poorly correlated
+7.42%
More